Tovorafenib Shows Prolonged Treatment-Free Intervals in Relapsed or Refractory BRAF-Altered Pediatric Glioma
Clinical Summary:
-
Design/Population: The phase 2 FIREFLY-1 trial evaluated tovorafenib, a CNS-penetrant type II RAF inhibitor, in patients aged 2 to 21 years with relapsed or refractory BRAF-altered pediatric low-grade glioma. Patients completing at least 26 treatment cycles could discontinue therapy and enter observation, with retreatment permitted upon disease progression.
-
Key Outcomes: At the May 2026 data snapshot, 72.5% of patients who entered observation remained off therapy, including 60% who had been treatment-free for at least 24 months. Among patients who restarted tovorafenib, no new safety findings were reported.
-
Clinical Relevance: These findings support the durability of clinical benefit with tovorafenib beyond planned treatment completion in relapsed or refractory BRAF-altered pediatric low-grade glioma, highlighting the potential for prolonged treatment-free intervals and retreatment when clinically indicated.
Updated results from the phase 2 FIREFLY-1 trial demonstrated prolonged treatment-free intervals following tovorafenib in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, with most patients entering observation remaining off therapy and no new safety findings reported with retreatment.
These results were presented by Daniel Landi, MD, Duke Health, Durham, North Carolina, at the Society for Neuro-Oncology (SNO) Annual Meeting.
In the registrational arm of this phase 2 trial, 77 patients aged 2 to 21 years received tovorafenib. Following at least 26 treatment cycles, each lasting 28 days, patients could discontinue treatment and enter an observation period. Treatment with tovorafenib could be reinitiated upon radiographic or clinical evidence of disease progression.
At analysis, median duration of response was 19.4 months, and 44 patients (57%) remained on treatment for at least 26 cycles. Median progression-free survival (PFS) was 16.6 months, primarily driven by radiographic changes, while median time to next treatment was 42.6 months and closely tracked clinical progression.
Among 39 patients who entered observation at the June 2025 data cutoff, 30 patients (77%) remained treatment-free for at least 12 months. Median treatment-free duration had not been reached. In an updated May 4, 2026, data snapshot, 40 patients had entered an observation period, including 1 additional patient since the previous data cutoff.
At a median follow-up of 26.4 months after the last dose of tovorafenib, 29 patients (72.5%) remained off therapy. Additionally, 24 patients (60%) had remained treatment-free for at least 24 months following their last dose.
Among the 40 patients who entered observation, 11 patients (28%) restarted tovorafenib following disease progression and remained on retreatment at the time of analysis. Median retreatment duration was 15.5 months, ranging from 1.4 to 23.7 months.
No new safety findings were identified among patients who restarted tovorafenib.
These findings suggest that clinical stability may persist beyond planned treatment completion in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma, with a substantial proportion remaining off therapy for prolonged periods.
The investigators concluded that longer-term FIREFLY-1 findings continue to support durable clinical benefit with tovorafenib beyond planned treatment completion, reinforcing its role in the management of relapsed or refractory BRAF-altered pediatric low-grade glioma.
Source:
Landi D, Khuong-Quang DA, Nystom K, et al. Updated 4-year results from the phase 2 FIREFLY-1 study: Clinical stability and durability of response to tovorafenib in relapsed/refractory pediatric low-grade glioma. Presented at the SNO Annual Meeting. November 12-15, 2026; Philadelphia, Pennsylvania. Abstract CTP-02.


